RSM2

India and China have been identified by pharmaceutical companies as the future markets that would support drug research and development in a cost efficient manner. This has become necessary as resources to conduct clinical studies dwindle, coupled with the fact that pharmaceutical industries are under pressure to deliver quality medicine, on time, to the public. Exploring and examining India and China’s potential in a stepwise fashion provides the opportunity to dissect the good, the bad and the ugly of globalization in a comparative approach. This paper will cover areas like ethics in the conduct of studies, good clinical practice (GCP), economic realities, ICH influence, intellectual property security and the role of government in global clinical trial.